Geron | GERN - Cash And Equivalent


Geron reported $79.44M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Amgen USD 9.13B 316M Dec/2025
Bio Techne USD 172.88M 27.92M Dec/2025
Cassava Sciences USD 106.08M 6.3M Sep/2025
Cytokinetics USD 225.47M 150.53M Sep/2025
Esperion Therapeutics USD 92.45M 6.39M Sep/2025
Exelixis USD 482.49M 106.19M Dec/2025
Genmab DKK 1.3B 323M Jun/2025
Geron USD 79.44M 553K Dec/2025
Gilead Sciences USD 7.33B 2.19B Sep/2025
Incyte USD 3.58B 650.78M Dec/2025
MacroGenics USD 80.13M 50.56M Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Novavax USD 268.02M 14.28M Sep/2025